论文部分内容阅读
目的 :观察肝动脉化疗栓塞 +门静脉插管化疗、灌输 CD3AK细胞治疗转移性肝癌的临床疗效及对机体免疫功能的影响。方法 :将 2 5例大肠癌肝转移患者随机分为 A,B两组 ,A组行肝动脉化疗栓塞 +门静脉插管化疗、灌输CD3AK细胞治疗 ,B组行肝动脉化疗栓塞 +门静脉插管化疗治疗。结果 :A组患者的细胞免疫指标在术后迅速恢复且维持在高水平状态 ,避免了机体由于手术打击而导致术后免疫力普遍降低的现象。而 B组术后细胞免疫功能较术前明显降低 ( P<0 .0 5 ) ,且恢复缓慢。A、B两组术后同期各指标相比较有显著性差异 ( P<0 .0 5 )。C组外周血单个核细胞的分布及体液免疫功能指标在术前、术后相比较无明显差异 ( P>0 .0 5 ) ,但均比 A、B组高。A组临床有效率为 80 % ,B组为 6 0 %。结论 :肝动脉化疗栓塞 +门静脉插管化疗、灌输 CD3AK细胞治疗转移性肝癌能提高临床疗效 ,提高肿瘤的 期切除率及迅速恢复、提高机体的细胞免疫功能
Objective: To observe the clinical efficacy of transcatheter arterial chemoembolization plus portal vein catheterization and infusion of CD3AK cells in the treatment of metastatic liver cancer and its effect on immune function. Methods: Twenty-five patients with liver metastasis of colorectal cancer were randomly divided into A and B groups. Group A received transcatheter hepatic artery chemoembolization plus portal vein catheterization and chemotherapy with CD3AK cells. Group B received transcatheter arterial chemoembolization plus portal vein catheterization treatment. Results: The cellular immunity index of group A recovered rapidly and remained at a high level after operation, avoiding the general decrease of postoperative immunity due to the surgery. The postoperative cellular immunity of group B was significantly lower than that before operation (P <0.05), and the recovery was slow. There was a significant difference between the two groups in the same period after operation (P <0.05). The distribution of peripheral blood mononuclear cells and the indexes of humoral immune function in C group had no significant difference before and after operation (P> 0.05), but higher than those in A and B groups. The clinical effective rate in group A was 80% and in group B was 60%. Conclusion: Transcatheter arterial chemoembolization combined with portal vein catheterization and chemotherapy of CD3AK cells in the treatment of metastatic HCC can improve the clinical curative effect, improve the rate of tumor resection and rapid recovery, and enhance the cellular immune function